Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,587.50
(
0.32%
)
US TECH 100
29,556.20
(
0.45%
)
Dow Jones
51,055.70
(
0.76%
)
Brent Oil
91.47
(
-0.77%
)
Bitcoin
73,452.45
(
-0.12%
)
News Focus
News Focus
Post# of 257657
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123037
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 190720

Friday, 05/01/2015 9:17:13 AM

Friday, May 01, 2015 9:17:13 AM

Post# of 257657

This is in line with GILD comments that they estimate 90% share for Q1. This is not an end of Q1 or current market share estimate like you assert - from the prepared remarks: "We estimate that at least 90% of genotype 1 HCV patients beginning treatment in the quarter started therapy on Harvoni".

In the Q&A, GILD said the 90% figure applied to April too, so it’s the current figure for all practical purposes.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today